Table III.
miRNAs differentially expressed in LC and HCC
| miRNA | Tissue sample | Median or mean | P-value | Function related | Detected expression | Reference |
|---|---|---|---|---|---|---|
| hsa-miR-206 | LC | 0.02369 | 0.0313 | Cell proliferation suppression, apoptosis | Low | [35, 36] |
| hsa-miR-637 | LC and HCC | 0.01019 and 0.006758 | 0.0156 and < 0.0001 | LIF gene inhibition, induced STAT3 phosphorylation | Low | [33] |
| hsa-miR-15b | HCC | 0.03091 | 0.0010 | Apoptosis, proliferation, survival and angiogenesis | Low | [37, 38] |
| hsa-miR-125b | HCC | 0.01632 | 0.0010 | Cell invasion, tumour metastasis, VEGF regulation | Low | [37, 42] |
| hsa-miR-423-3p | HCC | 0.02558 | 0.0010 | Cell proliferation, cell cycle | Low | [46, 48] |
| hsa-miR-424 | HCC | 0.004519 | 0.0313 | Angiogenesis regulation and cell invasion | Low | [51, 53] |
| hsa-miR-494 | HCC | 0.006319 | < 0.0001 | Cell cycle, sorafenib resistance, PTEN regulation | Low | [59] |
| hsa-miR-497 | HCC | 0.04621 | < 0.0001 | Invasion, proliferation, cell growth and apoptosis | Low | [63–66] |
| hsa-miR-612 | HCC | 0.00605 | 0.0078 | Metastasis suppressor | Low | [69] |
| hsa-miR-1255b | HCC | 0.00568 | 0.0156 | No functional study in the literature | Low | – |